JP2013525305A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525305A5
JP2013525305A5 JP2013505156A JP2013505156A JP2013525305A5 JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5 JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013505156 A JP2013505156 A JP 2013505156A JP 2013525305 A5 JP2013525305 A5 JP 2013525305A5
Authority
JP
Japan
Prior art keywords
antigen
multimeric ligand
subject
region
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013505156A
Other languages
English (en)
Japanese (ja)
Other versions
JP5975983B2 (ja
JP2013525305A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/032572 external-priority patent/WO2011130566A2/en
Publication of JP2013525305A publication Critical patent/JP2013525305A/ja
Publication of JP2013525305A5 publication Critical patent/JP2013525305A5/ja
Application granted granted Critical
Publication of JP5975983B2 publication Critical patent/JP5975983B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013505156A 2010-04-16 2011-04-14 固形腫瘍を処置するための方法 Expired - Fee Related JP5975983B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US32512710P 2010-04-16 2010-04-16
US61/325,127 2010-04-16
US35176010P 2010-06-04 2010-06-04
US61/351,760 2010-06-04
US201161442582P 2011-02-14 2011-02-14
US61/442,582 2011-02-14
PCT/US2011/032572 WO2011130566A2 (en) 2010-04-16 2011-04-14 Method for treating solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016060361A Division JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Publications (3)

Publication Number Publication Date
JP2013525305A JP2013525305A (ja) 2013-06-20
JP2013525305A5 true JP2013525305A5 (https=) 2014-05-01
JP5975983B2 JP5975983B2 (ja) 2016-08-23

Family

ID=44799326

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013505156A Expired - Fee Related JP5975983B2 (ja) 2010-04-16 2011-04-14 固形腫瘍を処置するための方法
JP2016060361A Withdrawn JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016060361A Withdrawn JP2016117770A (ja) 2010-04-16 2016-03-24 固形腫瘍を処置するための方法

Country Status (6)

Country Link
US (2) US20110287038A1 (https=)
EP (1) EP2558109A4 (https=)
JP (2) JP5975983B2 (https=)
AU (1) AU2011239569B2 (https=)
CA (1) CA2795947A1 (https=)
WO (1) WO2011130566A2 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073641A2 (en) 2003-02-18 2004-09-02 Kevin Slawin Induced activation in dendritic cells
CA3058450A1 (en) 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
CA2738031C (en) * 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters
ES2862340T3 (es) 2009-10-29 2021-10-07 Sanofi Mature Ip Nuevo uso antitumoral de cabazitaxel
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
MX350807B (es) 2011-11-29 2017-09-20 Genentech Inc Composiciones y metodos para el analisis de cancer de prostata.
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
CA2905352A1 (en) * 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
KR20150130284A (ko) * 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
EP2968448A4 (en) * 2013-03-15 2016-02-17 Univ Pennsylvania COMPOSITIONS USING HYPOXY-INDUCIBLE FACTOR 1-ALPHA AND METHOD OF USE THEREOF
JP6493692B2 (ja) 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
ES2791598T3 (es) 2013-06-05 2020-11-05 Bellicum Pharmaceuticals Inc Métodos para inducir apoptosis parcial utilizando polipéptidos de caspasa
JP6496472B2 (ja) * 2013-07-03 2019-04-03 三菱重工機械システム株式会社 車載器、及びスプーフィング検知方法
US10934346B2 (en) * 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
EP2940136A1 (en) * 2014-04-30 2015-11-04 QIAGEN GmbH Method for isolating poly(A) nucleic acids
AU2015312117A1 (en) * 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
JP6718444B2 (ja) 2014-11-03 2020-07-08 アカデミッシュ ザイケンホイス レイデン （エイチ．オー．ディー．エヌ． エルユーエムシー） Ｂｏｂ１に対して指向されるＴ細胞レセプターおよびその使用
US10975137B2 (en) * 2014-11-06 2021-04-13 University Of Maryland, Baltimore CD8a and t cell receptor variants and methods of using same in modulating immune cell responses
HK1245827B (en) * 2014-12-15 2020-06-19 Board Of Regents Of The University Of Texas System Methods for controlled activation or elimination of therapeutic cells
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2017015553A1 (en) * 2015-07-22 2017-01-26 University Of Washington Compositions and methods for producing pro-inflammatory macrophages
IL315940A (en) 2015-07-28 2024-11-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
US11266726B2 (en) * 2015-10-30 2022-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of HER2-expressing solid tumors
JP6904667B2 (ja) 2016-06-14 2021-07-21 日本光電工業株式会社 バイトブロック及びガスセンサキット
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
EP3621988A1 (en) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
EP3675902A4 (en) * 2017-08-28 2021-06-23 Board of Trustees of Michigan State University Compositions and methods of treating cancer and infections using bacteriophage and its mutants
WO2019067805A1 (en) 2017-09-27 2019-04-04 University Of Southern California NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY
WO2019113509A2 (en) 2017-12-08 2019-06-13 Bellicum Pharmaceuticals, Inc. Methods for enhancing and maintaining car-t cell efficacy
US20200308144A1 (en) 2017-12-20 2020-10-01 Bellicum Pharmaceuticals, Inc. Multimeric piperidine derivatives
US20220000921A1 (en) * 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof
CN114981409A (zh) 2019-09-03 2022-08-30 美洛德生物医药公司 用于基因组整合的方法和组合物
WO2021119538A1 (en) * 2019-12-11 2021-06-17 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods for manufacture and uses thereof
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021142305A2 (en) * 2020-01-10 2021-07-15 Coimmune, Inc. Methods of treating tumors
JP7735291B2 (ja) 2020-02-21 2025-09-08 エーアールエス ファーマシューティカルズ、インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
EP4161536A4 (en) 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
JP2023532304A (ja) 2020-07-01 2023-07-27 エーアールエス ファーマシューティカルズ オペレーションズ，インク． 抗ａｓｇｒ１抗体コンジュゲートおよびその使用
EP4240367A4 (en) 2020-11-04 2024-10-16 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2022197949A2 (en) 2021-03-17 2022-09-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
BR112023023642A2 (pt) 2021-05-11 2024-01-30 Myeloid Therapeutics Inc Métodos e composições para integração genômica

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2004073641A2 (en) * 2003-02-18 2004-09-02 Kevin Slawin Induced activation in dendritic cells
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
CA3058450A1 (en) * 2006-10-19 2008-04-24 Baylor College Of Medicine Generating an immune response by inducing cd40 and pattern recognition receptors
CN101888856B (zh) * 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
WO2009111507A1 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
WO2009151503A2 (en) * 2008-04-10 2009-12-17 University Of Florida Research Foundation, Inc. Compositions and methods for the treatment of a neoplasia
CA2738031C (en) * 2008-09-22 2022-11-29 Baylor College Of Medicine Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters

Similar Documents

Publication Publication Date Title
JP2013525305A5 (https=)
EP3368689B1 (en) Composition for modulating immune responses by use of immune cell gene signature
Brunell et al. Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities
CN112055695A (zh) 用于基因表达的纳米粒子和其用途
CN115297868B (zh) 用于编码核糖核酸的器官保护性表达和调节的组合物及方法
CN117721084A (zh) 靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法
WO2017075465A1 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
US11788093B2 (en) Chimeric antigen receptor t-cells expressing interleukin-8 receptor
KR102741572B1 (ko) 조직에서 코딩 리보핵산의 표적화된 전달, 발현 및 조절을 위한 조성물 및 방법
Wang et al. Different evasion strategies in multiple myeloma
Lee et al. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models
JP2022546282A (ja) Ｇｏｌｄ制御導入遺伝子による併用療法
Walters et al. Modulating expression of inhibitory and stimulatory immune ‘checkpoints’ using nanoparticulate-assisted nucleic acid delivery
CN107427581A (zh) T细胞群的改变方法
Snyder et al. Good CARMA: Turning bad tumor‐resident myeloid cells good with chimeric antigen receptor macrophages
KR20220092543A (ko) 암의 치료를 위한 의약, 조합 의약, 의약 조성물, 면역 응답성 세포, 핵산 전달 비히클 및 제품
Huang et al. Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer
Aljabali et al. The dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment
AU2024236982A1 (en) Mutants of a ligand-dependent corepressor (lcor) and uses thereof
Carreira et al. Nanomedicines as multifunctional modulators of melanoma immune microenvironment
JP2024516542A (ja) Ｍｈｃクラスｉペプチドを含む方法および組成物
Mokhtari et al. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers. 2021; 13: 3596
EP4711380A1 (en) Ligand-dependent corepressor, (lcor), mutants and fragments thereof, and uses for cancer therapy
Yuan et al. CD8+ T Cells in Gastrointestinal Cancer: a Perspective on Targeting MicroRNA
US20220372170A1 (en) Macrophage CAR (MOTO-CAR) In Immunotherapy